BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical ...
FierceBiotech2d
In 'surprise' termination, Genentech drops Nykode partnership for individualized cancer vaccine
Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...
What Analysts Are Saying About BioNTech Stock
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...
BioNTech SE’s Strategic Shift to Immuno-Oncology with BNT327: A Promising Investment Opportunity Amidst Stable COVID-19 Forecasts
In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...
BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...
BioNTech’s Strong Oncology Pipeline and COVID-19 Vaccine Performance Earns Buy Rating
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
BioSpace7d
BioNTech Handily Beats Q3 Expectations, Trims Full-Year Revenue Guidance
Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...
BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 ...
FiercePharma7d
BioNTech reports surprising COVID vaccine sales in Q3 but tempers expectations for annual sales
Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...
BioNTech lowers full-year revenue outlook on COVID-19 seasonality, inventory write-downs
German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, inventory write-downs and Pfizer charges.
BioNTech Beats Expectations, Gives Update on Cancer Drugs
BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.
BioNTech (BNTX) Scheduled to Post Quarterly Earnings on Monday
BioNTech (NASDAQ:BNTX – Get Free Report) will be announcing its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of ($1.06) per share ...